Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis According to The Autoantibody Status: A Retrospective Cohort Study

BMC Pulm Med.

Reductions in FVC and DLCO were similar in autoantibody-positive and autoantibody-negative patients with IPF treated with pirfenidone. Pirfenidone is effective in attenuating the progression of IPF, irrespective of the autoantibody status.